We have discussed the strategies for, and challenges associated with, the interpretation of noncoding putative enhancer SNPs as applied to the study of common variants identified by GWAS studies of common diseases and traits. As whole-genome sequencing becomes more prevalent, these same strategies will be necessary to elucidate the impact of rare noncoding mutations and to distinguish damaging from innocuous enhancer alterations.
